Total Confusion, page-15

Bob stated that there were 30,000 MRI machines World Wide.
Page 17 of Presentation " Makes total addressable market (TAM) of AU$500m per year in HER2 Breast Cancer immediately accessible.
My BOLD
We could reasonably expect to capture a % of that market over time. Not sure how much %. That is the spec nature of IBX.
Page 20 of ;Presentation " Each Cancer Test Billable
~$1,500 USD*
~80% Gross Margin* "
The margins right now are very good. Although they may come down.
There are other magsense nano particles to be developed for the other specific cancer types mentioned in the Presentation. These will take some time to get to market as they each need to go through the testing and approval stage. This will however provide growth prospects.
Based on the above:
30,000 tests per year at $1500 = $45mill *0.8 =$36m gross margin
60000 tests per year = $90mil l*0.8 = $72mill gross margin
90000 tests per year = $135m * 0.8 = $108 gross margin.
Remember that there are not a huge numbers of that particular cancer type when number crunching.
Just a guess on the number of tests (you pic a number) but the $$$ are ok but may take a while to build up. There may be follow up MRI's during after treatment. Gross margins may be lower. The ASX would not allow IBX to provide possible numbers.
Then there is the other specific types to develop which have to be tested and approved so will take some time but that = growth.
Rob was excited about Hand held scanners in the Doctors office but this sounds a way off.
Also briefly mentioned AI involvement at some point.
IBX naturally is a spec stock which i have a few $$ in.